MedTrace Logo

Screening of Cancer Patients to Assess Impact of COVID-19

NCT04373005 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 83

Last updated 2025-12-03

No results posted yet for this study

Summary

The purpose of this study is to investigate the impact of COVID -19 in the cancer patient population. This will be done by looking at the rate of asymptomatic COVID-19 infection in cancer patients receiving cancer therapy, as well as their immune response.

This is a sub-study of the U-DEPLOY study: UHN Umbrella Trial Defining Coordinated Approach to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery. U-DEPLOY helps to facilitate timely conduct of studies across the University Health Network (UHN) and other centers.

Conditions

Interventions

DIAGNOSTIC_TEST

Nasopharyngeal (NP) swab

A dry swab will be inserted through one nostril straight towards the back of the nasal passage and rotated gently before the swab is removed.

Sponsors & Collaborators

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Stephanie Lheureux, M.D. · Princess Margaret Cancer Centre

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-11
Primary Completion
2022-10-06
Completion
2022-10-06

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04373005 on ClinicalTrials.gov